jRCT1031240010招募中不适用
A multicenter prospective observational study in patients with HER2-positive advanced or metastatic breast cancer who achieved a Complete REsponse to trAstuzumab deruxtecan (A multicenter prospective observational study in patients with HER2-positive advanced or metastatic breast cancer who achieved a Complete REsponse to trAstuzumab deruxtecan (CREA))
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
入选标准
- •1.Patients who have diagnosed with HER2 positive inoperable or recurrent breast cancer
- •2.Patients who are at least 18 years of age at the time of obtaining consent
- •3.Patients who have been judged by their physicians to achieve complete response on imaging after receiving T-DXd
- •4.Patients who have given written consent to participate in this study
排除标准
- •Patients who are judged by investigators to be ineligible for this study
结局指标
主要结局
-
proportion of complete response: CR at 1-year: 1-year CR
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
JBCRG-S04 (JBCRG-S04)jRCT1070250028Eli Lilly Japan K.K.750
招募中
不适用
JBCRG-M10 (INDUCE trial)jRCTs041240039106
进行中（未招募）
1 期
A Phase 1b study of inhaled RCT1100 in Adults with Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary ClearanceCTIS2023-510521-14-00Recode Therapeutics Inc.12
已完成
不适用
Japanese multicenter REsearch of COVID-19 by assEmbling Real-world dataCOVID-19JPRN-UMIN000047056ippon Medical School Musashikosugi Hospital4,700
招募中
1 期
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumoursocally advanced or metastatic solid tumorsMedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864CTIS2023-508764-30-00Chugai Pharmaceutical Co. Ltd.150